Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

Autor: Abou-Alfa, G.K. ^*, Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H.Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W.P., Chen, Z., Hubner, R.A., Meyer, T., Sun, W., Harding, J.J., Hollywood, E.M., Ma, J., Wan, P.J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y., Chen, L.-T.

Publikováno v: In Annals of Oncology June 2018 29(6):1402-1408

Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM

Autor: Przystal, JM, Hajji, N, Khozoie, C, Renziehausen, A, Zeng, Q, Abaitua, F, Hajitou, A, Suwan, K, Want, E, Bomalaski, J, Szlosarek, P, O'Neill, K, Crook, T, Syed, N

Publikováno v: Cell Death & Disease
Cell Death and Disease, Vol 9, Iss 12, Pp 1-10 (2018)

Glioblastoma multiforme (GBM) remains a cancer with a poor prognosis and few effective therapeutic options. Successful medical management of GBM is limited by the restricted access of drugs to the central nervous system (CNS) caused by the blood brai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c296c17bc2d31f218b33cd1352dbdb3c
http://hdl.handle.net/10044/1/65835

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers

Autor: Beddowes, E, Spicer, J, Chan, PY, Khadeir, R, Corbacho, JG, Repana, D, Steele, JP, Schmid, P, Szyszko, T, Cook, G, Diaz, M, Feng, X, Johnston, A, Thomson, J, Sheaff, M, Wu, B-W, Bomalaski, J, Pacey, S, Szlosarek, PW

Publikováno v: Beddowes, E, Spicer, J, Chan, P Y, Khadeir, R, Garcia Corbacho, J, Repana, D, Steele, J P, Schmid, P, Szyszko, T, Cook, G, Diaz, M, Feng, X, Johnston, A, Thomason, J, Scheaff, M, Wu, B-W, Bomalaski, J, Pacey, S & Szlosarek, P W 2017, ' Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers ', Journal of Clinical Oncology, vol. 35, no. 16, pp. 1778-1785 . https://doi.org/10.1200/JCO.2016.71.3230

Purpose: Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) -negative tumors by converting arginine to citrulline and ammonia. The main aim of this study was to determine the recomm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16d3b5e67f628e85c2d09fcd2d9019a2
https://kclpure.kcl.ac.uk/ws/files/72158703/Phase_1_Dose_Escalation_Study_BEDDOWES_Publishedonline7April2017_GOLD_VoR_CC_BY_.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

MA 19.05 Pegylated Arginine Deiminase Potentiates PD-1/PD-L1 Immune Checkpoint Blockade in Malignant Mesothelioma

Autor: Szlosarek, P., Khadeir, R., Sheaff, M., Locke, M., Lau, K., Wu, B., Bomalaski, J., Martin, S., Quezada, S.

Publikováno v: In Journal of Thoracic Oncology November 2017 12(11) Supplement 2:S1884-S1884